HAEM5:Mantle cell lymphoma - Revision history

Bailey.Glen at 17:20, 3 July 2025

2025-07-03T17:20:22Z

← Older revision		Revision as of 12:20, 3 July 2025
Line 37:		Line 37:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:39, 25 May 2025

2025-05-25T21:39:51Z

← Older revision		Revision as of 16:39, 25 May 2025
Line 203:		Line 203:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 427:		Line 427:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 513:		Line 513:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:16, 25 May 2025

2025-05-25T20:16:09Z

← Older revision		Revision as of 15:16, 25 May 2025
Line 52:		Line 52:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Centrocytic lymphoma; malignant lymphoma, lymphocytic intermediate differentiation, diffuse
	\|}		\|}

Bailey.Glen at 17:39, 24 March 2025

2025-03-24T17:39:46Z

← Older revision		Revision as of 12:39, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Mantle cell lymphoma}}		{{DISPLAYTITLE:Mantle cell lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 16:		Line 15:

	The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas		The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Jennelleh at 13:15, 7 March 2025

2025-03-07T13:15:33Z

Show changes

Jennelleh at 13:12, 7 March 2025

2025-03-07T13:12:57Z

Show changes

Bailey.Glen at 18:51, 10 February 2025

2025-02-10T18:51:19Z

Show changes

Bailey.Glen at 18:23, 10 February 2025

2025-02-10T18:23:15Z

← Older revision		Revision as of 13:23, 10 February 2025
Line 83:		Line 83:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}</blockquote>


Line 107:		Line 107:


	<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>Arber, D.A., et al., ''Hematopathology''. 2017, Philadelphia, PA: Elsevier.</ref></blockquote>		<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>Arber, D.A., et al., ''Hematopathology''. 2017, Philadelphia, PA: Elsevier.</ref><blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
			</blockquote>
	</blockquote>		</blockquote>
	==Sites of Involvement==		==Sites of Involvement==
Line 263:		Line 269:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}</blockquote>


Line 293:		Line 299:


	<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal\|last=Martín-Garcia\|first=David\|last2=Navarro\|first2=Alba\|last3=Valdés-Mas\|first3=Rafael\|last4=Clot\|first4=Guillem\|last5=Gutiérrez-Abril\|first5=Jesús\|last6=Prieto\|first6=Miriam\|last7=Ribera-Cortada\|first7=Inmaculada\|last8=Woroniecka\|first8=Renata\|last9=Rymkiewicz\|first9=Grzegorz\|date=02 28, 2019\|title=CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/30538135\|journal=Blood\|volume=133\|issue=9\|pages=940–951\|doi=10.1182/blood-2018-07-862151\|issn=1528-0020\|pmc=6396173\|pmid=30538135}}</ref></blockquote>		<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal\|last=Martín-Garcia\|first=David\|last2=Navarro\|first2=Alba\|last3=Valdés-Mas\|first3=Rafael\|last4=Clot\|first4=Guillem\|last5=Gutiérrez-Abril\|first5=Jesús\|last6=Prieto\|first6=Miriam\|last7=Ribera-Cortada\|first7=Inmaculada\|last8=Woroniecka\|first8=Renata\|last9=Rymkiewicz\|first9=Grzegorz\|date=02 28, 2019\|title=CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/30538135\|journal=Blood\|volume=133\|issue=9\|pages=940–951\|doi=10.1182/blood-2018-07-862151\|issn=1528-0020\|pmc=6396173\|pmid=30538135}}</ref><blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
			</blockquote>
	</blockquote>		</blockquote>

Line 301:		Line 313:
	* Individual Region Genomic Gain/Loss/LOH		* Individual Region Genomic Gain/Loss/LOH
	* Characteristic Chromosomal Patterns		* Characteristic Chromosomal Patterns
	* Gene Mutations (SNV/INDEL)}}		* Gene Mutations (SNV/INDEL)}}</blockquote>

	* Median survival: 5 - 7 years		* Median survival: 5 - 7 years
Line 325:		Line 337:
	*** High-risk patients based on MIPI-C		*** High-risk patients based on MIPI-C

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 373:		Line 388:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Secondary chromosomal aberrations<ref>{{Cite journal\|last=C\|first=Royo\|last2=I\|first2=Salaverria\|last3=Em\|first3=Hartmann\|last4=A\|first4=Rosenwald\|last5=E\|first5=Campo\|last6=S\|first6=Beà\|date=2011\|title=The complex landscape of genetic alterations in mantle cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/21945515/\|language=en\|pmid=21945515}}</ref>		Secondary chromosomal aberrations<ref>{{Cite journal\|last=C\|first=Royo\|last2=I\|first2=Salaverria\|last3=Em\|first3=Hartmann\|last4=A\|first4=Rosenwald\|last5=E\|first5=Campo\|last6=S\|first6=Beà\|date=2011\|title=The complex landscape of genetic alterations in mantle cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/21945515/\|language=en\|pmid=21945515}}</ref>
Line 535:		Line 550:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 559:		Line 577:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*''CCND1'' rearrangement; t(11;14)(q13;q32)		*''CCND1'' rearrangement; t(11;14)(q13;q32)
Line 604:		Line 622:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==
Line 639:		Line 660:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}</blockquote>


Line 763:		Line 784:


	<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal\|last=Rosenquist\|first=R.\|last2=Beà\|first2=S.\|last3=Du\|first3=M.-Q.\|last4=Nadel\|first4=B.\|last5=Pan-Hammarström\|first5=Q.\|date=11 2017\|title=Genetic landscape and deregulated pathways in B-cell lymphoid malignancies\|url=https://pubmed.ncbi.nlm.nih.gov/28631441\|journal=Journal of Internal Medicine\|volume=282\|issue=5\|pages=371–394\|doi=10.1111/joim.12633\|issn=1365-2796\|pmid=28631441}}</ref></blockquote>		<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal\|last=Rosenquist\|first=R.\|last2=Beà\|first2=S.\|last3=Du\|first3=M.-Q.\|last4=Nadel\|first4=B.\|last5=Pan-Hammarström\|first5=Q.\|date=11 2017\|title=Genetic landscape and deregulated pathways in B-cell lymphoid malignancies\|url=https://pubmed.ncbi.nlm.nih.gov/28631441\|journal=Journal of Internal Medicine\|volume=282\|issue=5\|pages=371–394\|doi=10.1111/joim.12633\|issn=1365-2796\|pmid=28631441}}</ref><blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
			</blockquote>
	</blockquote>		</blockquote>
	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 789:		Line 816:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}</blockquote>
	Please refer to Gene Mutations (SNV/INDEL)		Please refer to Gene Mutations (SNV/INDEL)

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

Bailey.Glen at 22:29, 6 September 2024

2024-09-06T22:29:31Z

← Older revision		Revision as of 17:29, 6 September 2024
Line 18:		Line 18:
	__TOC__		__TOC__

	==~~Cancer Category / Type~~==		==WHO Classification of Disease==

	* [[HAEM4:Mature B-~~Cell Neoplasms]]~~		{\| class="wikitable"
			!Structure
	~~==Cancer Sub~~-~~Classification /~~ Subtype==		!Disease
			\|-
	* [[HAEM5:Mantle cell lymphoma]]		\|Book
			\|Haematolymphoid Tumours (5th ed.)
			\|-
			\|Category
			\|B-cell lymphoid proliferations and lymphomas
			\|-
			\|Family
			\|Mature B-cell neoplasms
			\|-
			\|Type
			\|N/A
			\|-
			\|Subtype(s)
			\|Mantle cell lymphoma
			\|}

	==Definition / Description of Disease==		==Definition / Description of Disease==

Bailey.Glen at 22:01, 6 September 2024

2024-09-06T22:01:56Z

Show changes